Plasma sphingolipid profiling , determined by tandem mass spectrometry , was performed in a randomized , double-blind , triple-crossover trial ( n = 12 ) of 5-week treatment periods with placebo or rosuvastatin ( 10 or 40 mg/d ) with 2-week washouts between treatments .